What is the maximum lifetime dose of Doxarubicin and Daunorubicin?

The maximum lifetime dose of Doxorubicin and Daunorubicin is generally recognized as 550 mg/m². This limit is set primarily due to the risk of cardiotoxicity associated with higher cumulative doses of these anthracycline chemotherapy agents. Prolonged exposure or exceeding this dose significantly increases the likelihood of developing serious heart problems, such as congestive heart failure.

The choice of 550 mg/m² serves as a guideline to ensure patient safety while balancing treatment effectiveness. It is essential for healthcare providers to monitor patients carefully during treatment and adhere to these dosing guidelines to minimize potential long-term adverse effects.

Other options fall short of this widely accepted maximum and thus do not align with clinical practice and guidelines established by oncologists and recognized cancer treatment protocols.